Skip to main content
🩹DERMATOLOGY

Skin & Genetic Skin Disease

Vitiligo, psoriasis, eczema, epidermolysis bullosa β€” from managing symptoms to repigmentation and at-home topical gene therapy

~125 million people live with psoriasis, ~230 million with atopic dermatitis and ~70 million with vitiligo; rare genetic skin diseases affect thousands but carry the heaviest burden.
CURE AVAILABLE
73/ 100
TO BROAD CURE

MILESTONEVyjuvek (beremagene geperpavec) is FDA-approved topical gene therapy for dystrophic epidermolysis bullosa.

LATESTEuropean Commission granted orphan designation to imsidolimab for generalized pustular psoriasis.

An approved cure exists for a major form of this disease Β· Not medical advice.

CURRENT STATUS

Dermatology has crossed a threshold no other specialty had reached: a redosable, at-home topical gene therapy β€” Vyjuvek β€” is FDA-approved and healing chronic wounds in dystrophic epidermolysis bullosa by restoring type VII collagen. Around it, an inflammatory-disease revolution is mature: topical and oral JAK inhibitors drive genuine repigmentation in vitiligo and rapid clearance in eczema; an oral TYK2 inhibitor and IL-23 biologics push plaque psoriasis to near-clear skin; IL-4/13 blockade transformed atopic dermatitis. Deep-learning image analysis and skin transcriptomics are ending trial-and-error prescribing by resolving inflammatory endotypes. The field has moved from suppressing rashes to correcting the gene and matching the mechanism.

KEY BREAKTHROUGHS

Vyjuvek (beremagene geperpavec) β€” first FDA-approved topical, redosable gene therapy, delivering COL7A1 for dystrophic epidermolysis bullosa

Ruxolitinib cream (Opzelura) β€” first topical JAK inhibitor to achieve meaningful repigmentation in vitiligo

Deucravacitinib (Sotyktu) β€” first oral TYK2 inhibitor for plaque psoriasis

IL-13/IL-4 and IL-23 biologics (dupilumab, risankizumab) transforming atopic dermatitis and psoriasis

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Dermatology Image Deep-LearningSkin Organoid ModelingBiomarker Response PredictionCRISPR / HSV Vector Design

KEY ORGANIZATIONS

Krystal BiotechIncyteBristol Myers SquibbPfizerLEO Pharma

KEY CLINICAL TRIALS

Vyjuvek (B-VEC) Label Expansion & At-Home Gene Therapy

View

Krystal Biotech

A redosable topical gene therapy using an engineered HSV-1 vector to deliver functional COL7A1 to the skin of people with dystrophic epidermolysis bullosa, restoring type VII collagen and healing chronic wounds β€” applied at home.

πŸ‘₯ Approved with ongoing pediatric/from-birth label expansion studiesπŸ“ US β€” EB specialty centers

Topical & Oral JAK Inhibitors for Vitiligo Repigmentation

View

Incyte / academic

Trials extending JAK inhibition (topical ruxolitinib and oral agents), often combined with phototherapy, to drive durable repigmentation across more of the body surface in vitiligo.

πŸ‘₯ Multiple Phase 2/3 vitiligo studiesπŸ“ US, EU β€” multicenter

TIMELINE ESTIMATE

Near-clear skin and vitiligo repigmentation: available now. Topical gene therapy for genetic skin disease: approved and expanding. Broad gene correction for genodermatoses: 3–7 years.

EXPLORE FULL CURE PROTOCOL